Agonist News and Research

RSS

Restless legs syndrome simulator

Restless legs syndrome (RLS) remains a common, yet often undiagnosed, neurological sensorimotor disorder, despite many years of research and increased disease recognition.

20 Jul 2007

COPD patients taking inhaled steroids are at greater risk for severe pneumonia

Patients with Chronic Obstructive Pulmonary Disease (COPD) are increasingly being prescribed inhaled corticosteroids to control exacerbations of the disease, but a new study finds that the anti-inflammatory drugs increase the chances that these patients will be hospitalized for pneumonia.

17 Jul 2007

Scientists take exciting approach for attacking cancers

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials.

10 Jul 2007

Abiraterone reduces levels of prostate specific antigen

For prostate cancer patients whose tumors have continued to grow despite medical or surgical castration, a new drug candidate that inhibits production of male hormones anywhere in the body is showing promise in early trials.

9 Jul 2007

Promising new therapy for protecting the fertility of women with cancer

A promising new therapy for protecting the fertility of women with cancer and auto-immune diseases such as lupus was revealed at the 23rd annual conference of the European Society of Human Reproduction and Embryology.

4 Jul 2007

SYMBICORT now available in the U.S. for asthma

AstraZeneca has announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

26 Jun 2007

SYMBICORT trial shows improved quality of life with asthma

New data demonstrated that the combination asthma therapy, SYMBICORT (budesonide/formoterol fumarate dihydrate), led to significant improvements in health-related quality of life (HRQL) and greater patient-reported satisfaction with asthma treatment, versus its monocomponents (budesonide or formoterol) or placebo.

24 May 2007

Drug treatment slows decline in lung function in COPD patients

Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference, on Tuesday, May 22.

22 May 2007

Clinical trial data for Perforomist Inhalation solution

Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).

22 May 2007

New breast cancer treatment may dispense with the need for chemotherapy

According to the latest research new hormone therapy drugs designed to treat breast cancer may dispense with the need for chemotherapy thus avoiding the nasty side effects associated with the treatment.

21 May 2007

Hormone treatment could cut need for chemo in some younger breast cancer patients

Around 5,500 pre-menopausal breast cancer patients could be offered a hormone drug that is shown to be as effective as traditional chemotherapy - and so avoid potential infertility and long-term menopausal side effects - according to a Cancer Research UK report published in The Lancet.

20 May 2007

FDA approves Dey, L.P.'s NDA for chronic obstructive pulmonary disease inhalation solution

Dey, L.P. has announced that the Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Perforomist (formoterol fumarate) Inhalation Solution for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).

15 May 2007

FDA approves skin patch designed to treat symptoms of early Parkinson's disease

Rotigotine is a drug not previously approved in the United States. Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease.

10 May 2007

Nitric oxide may be the key to why specific drugs for heart failure or asthma lose their effectiveness over time

A naturally occurring molecule in the body appears to control whether certain medications, such as beta adrenergic receptor agonists used in acute heart failure or in inhalers for asthma, lose their effectiveness over time.

4 May 2007

Phase III data on Safinamide in Parkinson's disease

Merck Serono S.A. has announced that Phase III data on safinamide, a new agent in Phase III development for the treatment of Parkinson's disease symptoms, were presented by Professor Fabrizio Stocchi at the American Academy of Neurology 59th Annual Meeting in Boston, Massachusetts, USA.

4 May 2007

Migraine sufferers may have form of brain damage

Scientists in the U.S. are suggesting that people with migraines may also be suffering from some form of brain damage.

2 May 2007

Submission of NDA for Istradefylline(KW-6002), an investigational anti-Parkinson's disease drug

Kyowa Hakko Kogyo Co. has announced that Kyowa Pharmaceutical, Inc., its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.

30 Apr 2007

Online gambling adds new risks for gamblers with Parkinson's disease

Parkinson's disease sufferers could be adversely affected by the growth of betting on the web because they are more likely to become gambling addicts, says a doctor writing in the British Medical Journal.

20 Apr 2007

Researchers finds meth receptor that could lead to therapy

A recently discovered signaling system in the brain has just been shown to be turned on by methamphetamine, an Oregon Health & Science University study found.

19 Apr 2007

Jefferson participates in global study to extend effectiveness of drug for Parkinson's

After Parkinson's disease patients use the drug levodopa or L-dopa for several years as a treatment for restoring the cellular communication that controls muscle movement by replacing lost dopamine, they begin to experience motor complications that include a shortened response to each dose of L-dopa.

19 Apr 2007